Clinical trials: HCC
Hepatocellular Carcinoma (HCC)
Biomarker Validation for Treatment Efficacy and Recurrence Prediction in Hepatocellular Carcinoma
Observational Model: Cohort Time Perspective: Other (prospective and retrospective data/sample collection) Primary Purpose: Other (biomarker validation for treatment response and recurrence prediction) Biospecimen Retention…
- Trial name
- NCT07840092
- Testing
- No investigational intervention. Participants receive standard clinical care. Clinical data, imaging/pathology information, and available biospecimens are collected for research.
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC
Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC
This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC…
- Trial name
- IMPACT31 (NCT07722741)
- Testing
- GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012
- Where
- 9 sites in United States, New Zealand
- Volunteers
- 90 people
- Sponsor
- Geneos Therapeutics
Hepatocellular Carcinoma (HCC)
TACE in Combination With Tislelizumab and Lenvatinib for Advanced HCC (CHANCE2602)
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with Tislelizumab and Lenvatinib in patients with advanced-stage hepatocellular carcinoma (HCC).
- Trial name
- CHANCE2602 (NCT07836309)
- Where
- China
- Volunteers
- 596 people
- Sponsor
- Zhongda Hospital
Unresectable Hepatocellular Carcinoma (HCC)
Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
Multimodal Thermal Therapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone for systemically untreated unresectable hepatocellular carcinoma (HCC)
- Trial name
- HLP1-1331 (NCT07596134)
- Testing
- Multimodal Thermal Therapy, Targeted and Immune Drugs
- Where
- 7 sites in China
- Volunteers
- 166 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma (HCC)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with…
- Trial name
- EMERALD-Y90 (NCT06040099)
- Testing
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
HCC - Hepatocellular Carcinoma, Diabetes
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in…
- Trial name
- NCT07557914
- Testing
- Epalrestat, Donafenib + Tislelizumab, HAIC
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Haibo Shao
Hepatocellular Carcinoma (HCC)
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
This is a prospective, single-arm, investigator-initiated clinical study designed to evaluate the safety and efficacy of lenalidomide in combination with targeted therapy and immunotherapy in patients with advanced hepatocellular…
- Trial name
- NCT07639138
- Testing
- Lenalidomide, Targeted Therapy, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Shunda Du
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hepatocellular Carcinoma (HCC)
Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a major therapeutic challenge. Although targeted therapy combined with immune checkpoint inhibitors has improved clinical outcomes, the objective response rate and conversion…
- Trial name
- NCT07832006
- Testing
- Irreversible Electroporation, Lenvatinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shunda Du
Hepatocellular Carcinoma (HCC)
Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.
The objectives of this study is to estimate the biological activity of combination chemotherapy and radiation versus radiation alone in patients with Hepato Cellular Carcinoma (HCC).
- Trial name
- DARTS (NCT07027436)
- Testing
- Chemotherapy/Radiation
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Hamilton Health Sciences Corporation
Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization)
Effectiveness of Enhanced Web-Based Health Education on Self-Care Practices and Quality of Life Among Patients With Hepatocellular Carcinoma Undergoing TACE
This randomized controlled trial aims to evaluate the effectiveness of enhanced web-based health education on self-care practices and quality of life among patients with hepatocellular carcinoma.
- Conditions
- Transarterial Chemoembolization, TACE(Transcatheter Arterial Chemoembolization), Web-based Intervention, Quality of Life
- Trial name
- NCT07825519
- Testing
- Enhanced Web-Based Health Education, Routine Health Education
- Where
- Vietnam
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- University Medical Center Ho Chi Minh City (UMC)
HCC, Resection
Optimizing Y90 Therapy for Radiation Lobectomy
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection.
- Conditions
- HCC, Resection, Transplant, Metastatic Cancer
- Trial name
- NCT04390724
- Testing
- Y90 radioembolization
- Where
- 2 sites in United States
- Volunteers
- 104 people
- Sponsor
- Northwestern University
Advanced Hepatocellular Carcinoma (HCC)
A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301…
- Trial name
- NCT07540832
- Testing
- WGI-0301, Lenvatinb
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
HCC - Hepatocellular Carcinoma
Defining the Ablative Dose for Y-90 TARE
This study is being done to help doctors improve how they treat liver tumors that cannot be removed by surgery or treated with standard ablation techniques.
- Trial name
- MARGIN (NCT07586046)
- Testing
- Yttrium-90 Radiation Segmentectomy (Y90 RS) using glass microspheres
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
HCC - Hepatocellular Carcinoma
Iparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
The purpose of this study is to learn how well a combination of iparomlimab and tuvonralimab (QL1706), lenvatinib, radiotherapy, and hepatic arterial infusion chemotherapy (HAIC) works and how safe it is for people with…
- Trial name
- NCT07776080
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Lenvatinib, Radiotherapy
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Advanced Hepatocellular Carcinoma (HCC)
Phase 2 Study of WGI-0301 for Advanced HCC
The purpose of this study is to determine the MTD of WGI-0301 in combination with Sorafenib for advanced Hepatocellular Carcinoma (HCC) and assess its safety and efficacy in adults with advanced unresectable HCC who have…
- Trial name
- NCT06309485
- Testing
- WGI-0301 at MTD/RP2D dose IV infusion, QW, WGI-0301 at MTD/RP2D -1 dose IV infusion, QW, Sorafenib 400 mg PO, BID continuously
- Where
- 9 sites in China, Hong Kong
- Volunteers
- 60 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepatocellular Carcinoma (HCC)
Efficacy Evaluation of Microwave Ablation Assisted by Diaphragm Hydrodissection for Hepatocellular Carcinoma and Comparative Analysis With Surgical
The goal of this observational study is to evaluate the local efficacy and safety of hydrodissection-assisted microwave ablation for patients with hepatocellular carcinoma, and to compare its therapeutic outcomes with surgical…
- Trial name
- NCT07815054
- Testing
- Microwave Ablation Assisted by Diaphragm Hydrodissection, Surgical Resection
- Volunteers
- 200 people
- Sponsor
- The First Hospital of Jilin University
Hepatocellular Carcinoma (HCC), Glypican-3
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.
- Conditions
- Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
- Trial name
- NCT07677774
- Testing
- GPC3-targeted PET/CT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
HCC - Hepatocellular Carcinoma
Real-world Insight Into Systemic Therapies for HCC: Single-center Study
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies
- Trial name
- HCC (NCT07814014)
- Where
- Egypt
- Volunteers
- 1,000 people
- Sponsor
- Mansoura University